Pfizer has agreed to pay $14.5 million to settle False Claims Act allegations related to the marketing of its drug Detrol, according to a news release from the Department of Justice.
This settlement resolves the last of a group of 10 whistleblower suits filed since 2003. The other nine suits were settled or dismissed in 2009 when Pfizer agreed to pay $2.3 billion to resolve civil claims and criminal charges regarding multiple drugs.
This specific settlement resolves allegations that Pfizer illegally marketed Detrol, a drug for the treatment of overactive bladder. Of the $14.5 million recovery, $11.9 million will go to the federal government and $2.6 million to state Medicaid programs. Under the qui tam provisions of the False Claims Act, whistleblowers will receive a $3.3 million share of the federal recovery.
Harvard Drug Group Pays $8M to Settle Claims of Failure to Report Suspicious Drug Orders
Teva Loses $144M Damages Claim to Baxter, Must Compensate Infected Patient $500M
This settlement resolves the last of a group of 10 whistleblower suits filed since 2003. The other nine suits were settled or dismissed in 2009 when Pfizer agreed to pay $2.3 billion to resolve civil claims and criminal charges regarding multiple drugs.
This specific settlement resolves allegations that Pfizer illegally marketed Detrol, a drug for the treatment of overactive bladder. Of the $14.5 million recovery, $11.9 million will go to the federal government and $2.6 million to state Medicaid programs. Under the qui tam provisions of the False Claims Act, whistleblowers will receive a $3.3 million share of the federal recovery.
Related Articles on Pharmaceutical Companies and Settlements:
Wisconsin's Ongoing Lawsuit Against Drugmakers Reaches Nearly $13M in SettlementsHarvard Drug Group Pays $8M to Settle Claims of Failure to Report Suspicious Drug Orders
Teva Loses $144M Damages Claim to Baxter, Must Compensate Infected Patient $500M